The Manufacturers Life Insurance Company Increases Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Key Points

• The Manufacturers Life Insurance Company increased its holdings in Regeneron Pharmaceuticals by 11.7% in the first quarter, owning approximately 398,236 shares worth $252.57 million.
• Regeneron Pharmaceuticals reported an earnings per share (EPS) of $12.89 for the last quarter, exceeding consensus estimates by $4.46, with revenues of $3.68 billion.
• The company declared a quarterly dividend of $0.88 per share, which reflects an annual yield of 0.6% and a payout ratio of 8.87%.

The Manufacturers Life Insurance Company raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 11.7% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 398,236 shares of the biopharmaceutical company's stock after acquiring an additional 41,826 shares during the period. The Manufacturers Life Insurance Company owned approximately 0.36% of Regeneron Pharmaceuticals worth $252,574,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of the business. Vanguard Group Inc. increased its holdings in Regeneron Pharmaceuticals by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company's stock worth $5,966,767,000 after acquiring an additional 121,545 shares in the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Regeneron Pharmaceuticals by 4.3% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company's stock worth $1,379,467,000 after acquiring an additional 89,579 shares in the last quarter. Goldman Sachs Group Inc. increased its holdings in Regeneron Pharmaceuticals by 18.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company's stock worth $724,984,000 after acquiring an additional 174,056 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Regeneron Pharmaceuticals by 30.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 982,064 shares of the biopharmaceutical company's stock worth $699,554,000 after acquiring an additional 226,952 shares in the last quarter. Finally, GAMMA Investing LLC increased its holdings in Regeneron Pharmaceuticals by 89,825.0% in the 1st quarter. GAMMA Investing LLC now owns 815,620 shares of the biopharmaceutical company's stock worth $517,291,000 after acquiring an additional 814,713 shares in the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on REGN shares. Redburn Atlantic raised shares of Regeneron Pharmaceuticals to a "strong-buy" rating in a report on Thursday, August 14th. Royal Bank Of Canada boosted their price target on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the stock a "sector perform" rating in a report on Monday, August 4th. Morgan Stanley reaffirmed an "overweight" rating and set a $761.00 target price (up previously from $754.00) on shares of Regeneron Pharmaceuticals in a report on Friday, August 1st. Sanford C. Bernstein upped their target price on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an "outperform" rating in a report on Wednesday, August 27th. Finally, Guggenheim upped their target price on shares of Regeneron Pharmaceuticals from $810.00 to $815.00 and gave the stock a "buy" rating in a report on Friday, August 1st. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $817.67.

Regeneron Pharmaceuticals Stock Down 0.5%

Shares of REGN stock traded down $2.80 during trading hours on Tuesday, reaching $577.90. 1,019,715 shares of the stock were exchanged, compared to its average volume of 1,103,477. The business's fifty day moving average is $558.63 and its two-hundred day moving average is $586.30. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 3.72. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,192.54. The firm has a market capitalization of $61.25 billion, a P/E ratio of 14.56, a P/E/G ratio of 1.93 and a beta of 0.35.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share for the quarter, topping analysts' consensus estimates of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3.68 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same period in the prior year, the firm earned $11.56 earnings per share. The business's quarterly revenue was up 3.6% compared to the same quarter last year. As a group, research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be paid a $0.88 dividend. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date is Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is currently 8.87%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.